Related references
Note: Only part of the references are listed.Optimal timing of PD-1 blockade in combination with oncolytic virus therapy
Hong-My Nguyen et al.
SEMINARS IN CANCER BIOLOGY (2022)
TGFβ biology in cancer progression and immunotherapy
Rik Derynck et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
Egle Ramelyte et al.
CANCER CELL (2021)
Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma
Juri Kiyokawa et al.
CLINICAL CANCER RESEARCH (2021)
The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
Shunchuan Zhang et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors
Amy Kwan et al.
MOLECULAR CANCER THERAPEUTICS (2021)
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
Brian B. Haines et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma
Gaku Takano et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment
Ibrahim Ragab Eissa et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs
Hitomi Ikeda et al.
JOURNAL OF VIROLOGY (2021)
Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas
Nidal B. Omar et al.
NEUROSURGICAL FOCUS (2021)
Development of Genome Editing Approaches against Herpes Simplex Virus Infections
Isadora Zhang et al.
VIRUSES-BASEL (2021)
An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma
Rui Ma et al.
CANCER RESEARCH (2021)
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
G. K. Friedman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Therapeutic Targeting of the Tumor Microenvironment
Leire Bejarano et al.
CANCER DISCOVERY (2021)
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma
Josep Malvehy et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
Bo Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy
Hena Khalique et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
Belen Blanco et al.
CLINICAL CANCER RESEARCH (2021)
Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and-2
Lauren A. Sadowski et al.
VIRUSES-BASEL (2021)
Oncolytic HSV: Underpinnings of Tumor Susceptibility
Chase Kangas et al.
VIRUSES-BASEL (2021)
Therapeutic cancer vaccines
Mansi Saxena et al.
NATURE REVIEWS CANCER (2021)
The efficacy of a third-generation oncolytic herpes simplex viral therapy for an HPV-related uterine cervical cancer model
Masahiro Kagabu et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)
Oncolytic activity of HF10 in head and neck squamous cell carcinomas
Shinichi Esaki et al.
CANCER GENE THERAPY (2020)
Challenges in assessing solid tumor responses to immunotherapy
Louis F. Chai et al.
CANCER GENE THERAPY (2020)
The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology
Linkang Cai et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity
Wen Zhang et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy
Hong-My Nguyen et al.
CELLS (2020)
Targeting the MAPK Pathway in KRAS-Driven Tumors
Matthias Drosten et al.
CANCER CELL (2020)
Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade
Chaolong Lin et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Delivery and Biosafety of Oncolytic Virotherapy
Lizhi Li et al.
FRONTIERS IN ONCOLOGY (2020)
Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis
Shanawaz M. Ghouse et al.
FRONTIERS IN ONCOLOGY (2020)
Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors
Joshua D. Bernstock et al.
HUMAN GENE THERAPY (2020)
Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene
E. Antonio Chiocca et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability
Edward M. Kennedy et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
Eva Crespo-Rodriguez et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Oncolytic herpesvirus therapy for mesothelioma - A phase I/IIa trial of intrapleural administration of HSV1716
Sarah J. Danson et al.
LUNG CANCER (2020)
Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
Maria De Lucia et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells
Xinping Fu et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
Marilin S. Koch et al.
CANCERS (2020)
Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes
Dmitry V. Chouljenko et al.
BIOMEDICINES (2020)
Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
Laura Menotti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Cytokines in the Treatment of Cancer
Kevin C. Conlon et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model
Francesco Alessandrini et al.
ONCOGENE (2019)
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells
Lei Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition
Victoria A. Jennings et al.
MOLECULAR THERAPY (2019)
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
Praveen K. Bommareddy et al.
ONCOIMMUNOLOGY (2019)
Optimizing oncolytic virotherapy in cancer treatment
Kevin Harrington et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial
Keri A. Streby et al.
MOLECULAR THERAPY (2019)
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
Suzanne Thomas et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
Carmela Passaro et al.
CLINICAL CANCER RESEARCH (2019)
Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells
Xing Liu et al.
JOURNAL OF VIROLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1
Yujie Zhu et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival
Paola Sette et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives
Satoru Taguchi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
Stephen J. Russell et al.
CANCER CELL (2018)
Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice
Richi Nakatake et al.
CANCER SCIENCE (2018)
Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma
Hiroshi Nakashima et al.
CLINICAL CANCER RESEARCH (2018)
Armed oncolytic viruses: A kick-start for anti-tumor immunity
J. F. de Graaf et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells
Cole Peters et al.
JOURNAL OF VIROLOGY (2018)
Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory
Mohammed G. Ghonime et al.
TRANSLATIONAL ONCOLOGY (2018)
HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
Laura Menotti et al.
VIRUSES-BASEL (2018)
A novel oncolytic herpes simplex virus armed with the carboxyl-terminus of murine MyD116 has enhanced antitumour efficacy against human breast cancer cells
Lin Cheng et al.
ONCOLOGY LETTERS (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
Valerio Leoni et al.
PLOS PATHOGENS (2018)
MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
Praveen K. Bommareddy et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K. Bommareddy et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models
Shinichi Esaki et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Herpes Simplex Encephalitis: an Update
John W. Gnann et al.
CURRENT INFECTIOUS DISEASE REPORTS (2017)
TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma
Brian Hutzen et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates
Kevin A. Cassady et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
Ibrahim Ragab Eissa et al.
Frontiers in Oncology (2017)
Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
Chun-Yu Chen et al.
SCIENTIFIC REPORTS (2017)
Local Delivery of OncoVEXmGM-CSF Generates Systemic AntitumorImmuneResponses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade
Achim K. Moesta et al.
CLINICAL CANCER RESEARCH (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
Dipongkor Saha et al.
CANCER CELL (2017)
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
Keri A. Streby et al.
CLINICAL CANCER RESEARCH (2017)
Imaging Manifestations of Pseudoprogression in Metastatic Melanoma Nodes Injected with Talimogene Laherparepvec: Initial Experience
C. Zamora et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2017)
Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity
Yoshihiro Hotta et al.
ONCOLYTIC VIROTHERAPY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells
A. Takasu et al.
CANCER GENE THERAPY (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Retargeting Strategies for Oncolytic Herpes Simplex Viruses
Gabriella Campadelli-Fiume et al.
VIRUSES-BASEL (2016)
IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice
Eric D. Thomas et al.
JOURNAL OF OVARIAN RESEARCH (2016)
The oncolytic virus ΔPK has multimodal anti-tumor activity
Laure Aurelian et al.
PATHOGENS AND DISEASE (2016)
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
Daxa M. Patel et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2016)
TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response
Jianfeng Han et al.
CANCER RESEARCH (2015)
In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf
Linda Hammerich et al.
MOLECULAR ONCOLOGY (2015)
Designing herpes viruses as oncolytics
Cole Peters et al.
MOLECULAR THERAPY-ONCOLYTICS (2015)
Therapeutic Effect on Bladder Cancer with a Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex Virus
Kwan Joong Joo et al.
BLADDER CANCER (2015)
Interleukin 12: still a promising candidate for tumor immunotherapy?
Witold Lasek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Both plasmacytoid dendritic cells and monocytes stimulate natural killer cells early during human herpes simplex virus type 1 infections
Karin Vogel et al.
IMMUNOLOGY (2014)
Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy
Samuel T. Workenhe et al.
MOLECULAR THERAPY (2014)
A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
James M. Markert et al.
MOLECULAR THERAPY (2014)
A Novel Oncolytic Herpes Simplex Virus Type 2 Has Potent Anti-Tumor Activity
Qian Zhao et al.
PLOS ONE (2014)
Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman Primates
Justin C. Roth et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2014)
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
Tooba A. Cheema et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice
E. Reisoli et al.
CANCER GENE THERAPY (2012)
Treatment of breast cancer stem cells with oncolytic herpes simplex virus
J. Li et al.
CANCER GENE THERAPY (2012)
Response to Intra-Arterial Oncolytic Virotherapy with the Herpes Virus NV1020 Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography
Daniel Y. Sze et al.
HUMAN GENE THERAPY (2012)
Effect of γ34.5 Deletions on Oncolytic Herpes Simplex Virus Activity in Brain Tumors
Ryuichi Kanai et al.
JOURNAL OF VIROLOGY (2012)
The Histone Deacetylase Inhibitor Valproic Acid Lessens NK Cell Action against Oncolytic Virus-Infected Glioblastoma Cells by Inhibition of STAT5/T-BET Signaling and Generation of Gamma Interferon
Christopher A. Alvarez-Breckenridge et al.
JOURNAL OF VIROLOGY (2012)
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
Christopher A. Alvarez-Breckenridge et al.
NATURE MEDICINE (2012)
A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
A. Nakao et al.
CANCER GENE THERAPY (2011)
A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells
Ryuichi Kanai et al.
CLINICAL CANCER RESEARCH (2011)
Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver
Sunil K. Geevarghese et al.
HUMAN GENE THERAPY (2010)
Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice
Y. Kulu et al.
CANCER GENE THERAPY (2009)
Human Glioblastoma-Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors
Hiroaki Wakimoto et al.
CANCER RESEARCH (2009)
Differences in the Regulatory and Functional Effects of the Us3 Protein Kinase Activities of Herpes Simplex Virus 1 and 2
Tomomi Morimoto et al.
JOURNAL OF VIROLOGY (2009)
A Herpes Oncolytic Virus Can Be Delivered Via the Vasculature to Produce Biologic Changes in Human Colorectal Cancer
Yuman Fong et al.
MOLECULAR THERAPY (2009)
Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre- and Post-tumor Resection for Recurrent GBM
James M. Markert et al.
MOLECULAR THERAPY (2009)
Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy
Kaitlyn J. Kelly et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma
Alastair T. M. Mace et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2008)
Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10
Daisuke Watanabe et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2008)
Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses
Susan Varghese et al.
CANCER RESEARCH (2007)
Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-akt-targeting molecular therapeutics
Ta-Chiang Liu et al.
CLINICAL CANCER RESEARCH (2007)
Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses
A. C. Shah et al.
GENE THERAPY (2007)
Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy
H. Kasuya et al.
CANCER GENE THERAPY (2007)
Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model
Hongtao Li et al.
JOURNAL OF GENE MEDICINE (2007)
Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashil promoter in the treatment of malignant glioma
Ryuichi Kanal et al.
HUMAN GENE THERAPY (2007)
Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma
Hongtao Li et al.
CLINICAL CANCER RESEARCH (2007)
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver
Nancy Kemeny et al.
HUMAN GENE THERAPY (2006)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases
Toshihiko Kuroda et al.
BMC BIOTECHNOLOGY (2006)
Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer
Hideto Kimata et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS
William W. Gierasch et al.
JOURNAL OF VIROLOGICAL METHODS (2006)
Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung
S Varghese et al.
CLINICAL CANCER RESEARCH (2006)
A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus
Xinping Fu et al.
MOLECULAR THERAPY (2006)
Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13α2 receptor
GY Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models
K Terada et al.
GENE THERAPY (2006)
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers
S Varghese et al.
CANCER GENE THERAPY (2006)
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model
EK Hellums et al.
NEURO-ONCOLOGY (2005)
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor
H Kambara et al.
CANCER RESEARCH (2005)
Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice
RB Liu et al.
CANCER RESEARCH (2005)
Herpes simplex virus protein kinase US3 activates and functionally overlaps protein kinase A to block apoptosis
L Benetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12
RJ Wong et al.
CLINICAL CANCER RESEARCH (2004)
HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival
S Harrow et al.
GENE THERAPY (2004)
Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice
H Takakuwa et al.
ARCHIVES OF VIROLOGY (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer
T Endo et al.
CANCER GENE THERAPY (2002)
A herpes simplex virus type 1 γ34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals
I Mohr et al.
JOURNAL OF VIROLOGY (2001)
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
T Todo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Intralesional injection of herpes simplex virus 1716 in metastatic melanoma
RM MacKie et al.
LANCET (2001)
Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma
RJ Wong et al.
HUMAN GENE THERAPY (2001)
Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy
KA Delman et al.
HUMAN GENE THERAPY (2000)
Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model
ES Lambright et al.
MOLECULAR THERAPY (2000)
Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice
P Sundaresan et al.
JOURNAL OF VIROLOGY (2000)
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
R Rampling et al.
GENE THERAPY (2000)
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
JM Markert et al.
GENE THERAPY (2000)
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
JN Parker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
